BRITISH COLUMBIA
CENTRE *for* **EXCELLENCE**
in **HIV/AIDS**

HIV MONITORING
QUARTERLY REPORT
FOR NORTHERN HEALTH

SECOND QUARTER 2016

BC Centre for Disease Control
An agency of the Provincial Health Services Authority

First Nations Health Authority
Health through wellness

fraserhealth

Interior Health
Every person matters

island health

northern health
the northern way of caring

Providence
HEALTH CARE
How you want to be treated.

Vancouver
CoastalHealth
Promoting wellness. Ensuring care.

Foreword

As part of the BC Centre for Excellence (BC-CFE) in HIV/AIDS's mandate to evaluate the outcomes of STOP HIV/AIDS programming in BC, we have developed quarterly HIV/AIDS monitoring reports. These reports provide up-to-date data on a variety of key HIV-related surveillance and treatment indicators. Selection of these indicators was achieved through a collaborative process with various Health Authority (HA) representatives. There are six reports in total, one for each HA and one for the province of BC as a whole. In addition, there is a technical report which explains how each HIV indicator is calculated. Data used in these reports come from the British Columbia Centre for Disease Control (BCCDC), MSP billings, hospitalization data from the Discharge Abstract Database, the Sunquest Laboratory database at the Provincial Public Health Microbiology and Reference Laboratory, Providence Health Care laboratory and the BC-CFE Drug Treatment Program (DTP) Database.

The objectives of these reports are to:

1. Provide timely HA-specific information on key HIV indicators which will guide and inform HIV leaders and innovators in the development of future HIV interventions and programs which will ultimately lead to decreasing the burden of HIV in BC. The indicators will reflect ongoing or past successful public health interventions and highlight areas in the HIV care spectrum which require further attention and support.

2. Highlight limitations in our current data due to incomplete or time lagged data and to develop future strategies to improve complete and timely data capture.

These reports are produced for the benefit of individual HA's. As such, we are enthusiastic about your involvement and cooperation regarding the development of these monitoring reports. Please forward your comments and queries to Irene Day, Director of Operations at the BC-CFE at iday@cfenet.ubc.ca.

List of Indicators

Table of Contents

Acknowledgements and Contributions

Membership of the STOP HIV/AIDS Technical Monitoring Committee–BC-CfE

Dr. Rolando Barrios, *Chair*, BC-CFE

Dr. Kate Heath, BC-CFE

Dr. Bohdan Nosyk, BC-CFE

Dr. Viviane Dias Lima, BC-CFE

Irene Day, BC-CFE

Dr. Jean Shoveller, BC-CFE

Dr. Jason Wong, BCCDC

Dr. Mel Krajden, BCCDC

Salman Klar, FHA

Jennifer May-Hadford, IHA

Kari Harder, NHA

Dr. Neora Pick, PHSA

Dr. Reka Gustafson, VCHA

Dr. Melanie Rusch, VIHA

The Seek and Treat for Optimal Prevention (STOP) HIV/AIDS BC Provincial Program: A Note on Monitoring and Interpreting HIV Indicators

The Seek and Treat for Optimal Prevention (stop) of Hiv/Aids programme is a provincial initiative to improve hiv diagnosis and care delivery in bc through increased hiv-specific funding to all Health Service Delivery Areas (hsda's) across bc. The stop provincial programme is an expansion of a four-year stop pilot project which was implemented in two Health Service Delivery Areas in March 2010; the Vancouver hsda which bears the largest burden of the hiv epidemic in the province and the Northern Interior hsda which bears a high burden of hiv-related mortality. The stop pilot project demonstrated the urgent need for improved efforts in early diagnosis of hiv and timely initiation of antiretroviral therapy (art) initiation.

The expansion to a province-wide programme was announced on November 30th, 2013 by the bc Ministry of Health with roll out of funding beginning on April 1st, 2013. This funding is intended to be used in the implementation and evaluation of hiv-related diagnosis and care initiatives within individual ha's. Goals of the project include: 1. A reduction in the number of new hiv infections in bc; 2. Improvements in the quality, effectiveness, and reach of hiv prevention services; 3. An increase in early diagnosis of hiv; 4. A reduction in aids cases and hiv-related mortality.

The goals of ha-led stop-funded initiatives are to work toward achieving these goals. To these ends some outcome measures or indicators of progress have been drafted that should be considered in the design and implementation phases of these initiatives.

HIV Testing Episodes and Rates

In this section, the number of HIV test episodes and point of care (POC) HIV tests conducted each quarter in BC is shown. In general terms the goal is to increase the number of tests performed and to maximize testing efficiency. Test episodes are allocated by region according to where the test is performed.

Indicator 1. HIV Testing Episodes

Figure 1.1   HIV Test Episodes for Northern Health

	Q3 2011	Q4	Q1 2012	Q2	Q3	Q4	Q1 2013	Q2	Q3	Q4	Q1 2014	Q2	Q3	Q4	Q1 2015	Q2	Q3	Q4	Q1 2016	Q2
Northern Health	1.9	1.9	2.3	2.2	2.2	2.3	2.7	2.7	2.6	2.6	3.1	3.0	2.9	3.0	3.7	3.2	3.2	3.2	3.7	3.3

Figure 1.2   HIV Test Episodes by Gender for Northern Health [1,2]

	Q3 2011	Q4	Q1 2012	Q2	Q3	Q4	Q1 2013	Q2	Q3	Q4	Q1 2014	Q2	Q3	Q4	Q1 2015	Q2	Q3	Q4	Q1 2016	Q2
Female	1.0	1.0	1.2	1.1	1.2	1.2	1.3	1.4	1.3	1.3	1.6	1.5	1.5	1.5	1.9	1.6	1.6	1.6	1.9	1.7
Male	0.8	0.8	1.1	1.0	1.0	1.1	1.2	1.2	1.1	1.2	1.4	1.3	1.3	1.4	1.6	1.4	1.5	1.4	1.6	1.5
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Figure 1.3 HIV Test Episodes by Age Category for Northern Health [1,2]

	Q3 2011	Q4	Q1 2012	Q2	Q3	Q4	Q1 2013	Q2	Q3	Q4	Q1 2014	Q2	Q3	Q4	Q1 2015	Q2	Q3	Q4	Q1 2016	Q2
< 30	0.8	0.8	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0	0.9	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.0
30–39	0.4	0.4	0.5	0.5	0.5	0.4	0.6	0.5	0.5	0.5	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.7	0.6
40–49	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.5	0.4	0.4	0.5	0.6	0.5	0.5	0.5	0.6	0.5
≥ 50	0.3	0.3	0.5	0.4	0.5	0.5	0.6	0.6	0.6	0.7	0.9	0.8	0.8	0.9	1.3	0.9	0.9	0.9	1.1	1.1

Figure 1.4 Point-of-Care HIV Tests for Northern Health

	Q3 2011	Q4	Q1 2012	Q2	Q3	Q4	Q1 2013	Q2	Q3	Q4	Q1 2014	Q2	Q3	Q4	Q1 2015	Q2	Q3	Q4	Q1 2016	Q2
Northern Health	54	52	83	74	60	65	137	123	151	110	139	137	91	102	183	71	125	124	144	94

---

1   *Data Source: The BC Public Health Microbiology and Reference Laboratory (BCPHMRL) courtesy of the BC Centre for Disease Control (BCCDC).*

   Limitation: Repeat tests in individuals who test using various identifiers may not be identified and these individuals may be counted more than once.

2   *Testing does not include point of care tests.*

Figure 1.5   HIV Test Episodes for Northern Health by HSDA [1]

	Q3 2011	Q4	Q1 2012	Q2	Q3	Q4	Q1 2013	Q2	Q3	Q4	Q1 2014	Q2	Q3	Q4	Q1 2015	Q2	Q3	Q4	Q1 2016	Q2
Northeast	0.4	0.4	0.5	0.5	0.4	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.5	0.5	0.6	0.6	0.5
Northern Interior	1.0	1.1	1.4	1.2	1.3	1.4	1.6	1.6	1.6	1.6	2.0	1.9	1.8	1.9	2.6	2.0	2.0	1.9	2.3	2.2
Northwest	0.4	0.4	0.5	0.5	0.5	0.5	0.6	0.5	0.5	0.6	0.6	0.6	0.6	0.7	0.7	0.7	0.6	0.7	0.8	0.7

12

Figure 1.6   HIV Test Episodes for Non-prenatal Females in Northern Health by HSDA [1,2]

	Q3 2011	Q4	Q1 2012	Q2	Q3	Q4	Q1 2013	Q2	Q3	Q4	Q1 2014	Q2	Q3	Q4	Q1 2015	Q2	Q3	Q4	Q1 2016	Q2
Northeast	0.3	0.2	0.3	0.3	0.2	0.2	0.3	0.3	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.3
Northern Interior	0.5	0.6	0.7	0.6	0.6	0.7	0.7	0.8	0.8	0.7	1.0	0.9	0.9	0.9	1.3	1.0	1.0	0.9	1.2	1.1
Northwest	0.3	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.3	0.3	0.3	0.3	0.4	0.4	0.3	0.4	0.5	0.3

Figure 1.7   HIV Test Episodes for Males in Northern Health by HSDA [1,2]

	Q3 2011	Q4	Q1 2012	Q2	Q3	Q4	Q1 2013	Q2	Q3	Q4	Q1 2014	Q2	Q3	Q4	Q1 2015	Q2	Q3	Q4	Q1 2016	Q2
Northeast	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.3
Northern Interior	0.5	0.5	0.6	0.6	0.6	0.7	0.7	0.7	0.7	0.7	0.9	0.8	0.8	0.8	1.1	0.9	0.9	0.8	1.0	1.0
Northwest	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3

Indicator 2. HIV Testing Rates

Figure 2.1   Rate of HIV Testing for Northern Health and HSDAs [2]

	2009	2010	2011	2012	2013	2014	2015
All Northern Health	2290.7	2349.0	2431.8	2909.8	3333.0	3825.8	4347.2
Northeast	2289.8	2246.2	2343.4	2563.9	2621.4	2548.7	2946.7
Northern Interior	2360.2	2450.0	2563.9	3222.0	3801.1	4644.3	5290.5
Northwest	2158.9	2248.3	2259.0	2633.2	3109.1	3499.8	3914.8

Figure 2.2   Rate of HIV Testing by Gender for Northern Health [2]

	2009	2010	2011	2012	2013	2014	2015
Female	2412.8	2542.7	2622.2	3102.4	3618.7	4196.5	4712.5
Male	2106.3	2123.3	2213.0	2685.1	3021.7	3427.5	3934.9

14

Figure 2.3   Rate of HIV Testing by Age Category for Northern Health [2]

	2009	2010	2011	2012	2013	2014	2015
< 30	2400.7	2474.8	2611.1	2971.6	3122.6	3201.6	3494.6
30–39	4263.7	4336.5	4440.8	4754.5	5245.2	5811.3	6019.4
40–49	2448.1	2541.9	2670.1	3215.1	3614.2	4331.3	5113.3
≥ 50	1198.4	1243.5	1291.6	1976.9	2719.3	3576.2	4356.9

2   *Testing does not include point of care tests.*

New HIV Diagnoses

Trends in HIV diagnoses by gender and exposure category are described. Interpreting HIV diagnoses must be done with consideration that trends are influenced by both changes in testing rate as well as changes in transmission rates. It is important to note that new HIV diagnoses cases and rates are not synonymous with HIV incidence as a person may have become infected with HIV long before they tested positive for HIV. However, as there is no reliable method for measuring HIV incidence, we follow trends in HIV diagnoses.

Indicator 3. New HIV Diagnoses

Figure 3.1   New HIV Diagnoses for Northern Health [3]

	Q3 2011	Q4	Q1 2012	Q2	Q3	Q4	Q1 2013	Q2	Q3	Q4	Q1 2014	Q2	Q3	Q4	Q1 2015	Q2	Q3	Q4	Q1 2016	Q2
Northern Health	5	5	5	4	3	0	3	8	3	3	2	5	4	2	1	2	2	1	2	4
by Provider Address	*5*	*6*	*5*	*4*	*3*	*0*	*3*	*8*	*3*	*3*	*2*	*5*	*3*	*2*	*1*	*2*	*2*	*1*	*3*	*4*

Figure 3.2   New HIV Diagnoses for Northern Health by Gender [3]

	Q3 2011	Q4	Q1 2012	Q2	Q3	Q4	Q1 2013	Q2	Q3	Q4	Q1 2014	Q2	Q3	Q4	Q1 2015	Q2	Q3	Q4	Q1 2016	Q2
Female	1	3	1	2	0	0	0	3	1	0	1	0	1	1	0	0	2	1	2	0
Male	4	2	4	2	3	0	3	5	2	3	1	5	3	1	1	2	0	0	0	4

3   *Data Source: BCCDC When present, "By Provider Address" is graphed as dashed line in same colour.*

16

Figure 3.3   New HIV Diagnoses for Northern Health by Age Category [3]

	Q3 2011	Q4	Q1 2012	Q2	Q3	Q4	Q1 2013	Q2	Q3	Q4	Q1 2014	Q2	Q3	Q4	Q1 2015	Q2	Q3	Q4	Q1 2016	Q2
< 30	1	2	1	0	0	0	0	2	0	0	0	1	2	1	0	0	0	0	2	0
30–39	1	2	0	1	0	0	0	5	0	1	1	0	0	1	0	2	1	0	0	1
40–49	2	0	1	2	2	0	1	0	0	1	1	0	0	0	1	0	0	0	0	1
≥ 50	1	1	3	1	1	0	2	1	3	1	0	4	2	0	0	0	1	1	0	2

Figure 3.4   New HIV Diagnoses for Northern Health by Exposure Category [3,4]

	Q3 2011	Q4	Q1 2012	Q2	Q3	Q4	Q1 2013	Q2	Q3	Q4	Q1 2014	Q2	Q3	Q4	Q1 2015	Q2	Q3	Q4
MSM (men who have sex with men)	1	1	0	0	1	0	1	1	0	1	0	1	1	0	0	0	0	0
PWID (persons who inject drugs)	1	3	3	2	1	0	0	2	0	2	1	0	0	1	1	1	0	0
HET (heterosexual)	3	1	2	2	0	0	2	5	2	0	1	3	1	1	0	1	1	0
Other (other exposure identified)	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	0
NIR/Unknown (no identified exposure)	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	1	1

Figure 3.5   New HIV Diagnoses for Northern Health by HSDA [3]

	Q3 2011	Q4	Q1 2012	Q2	Q3	Q4	Q1 2013	Q2	Q3	Q4	Q1 2014	Q2	Q3	Q4	Q1 2015	Q2	Q3	Q4	Q1 2016	Q2
Northeast	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
by Provider Address	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*1*	*0*	*1*	*0*	*0*	*0*	
Northern Interior	4	4	2	4	2	0	3	6	2	3	1	2	3	1	1	1	1	1	2	3
by Provider Address	*4*	*4*	*2*	*4*	*2*	*0*	*3*	*7*	*2*	*3*	*1*	*3*	*3*	*1*	*1*	*1*	*1*	*1*	*3*	*3*
Northwest	1	1	3	0	1	0	0	2	1	0	1	3	1	0	0	1	0	0	0	1
by Provider Address	*1*	*2*	*3*	*0*	*1*	*0*	*0*	*1*	*1*	*0*	*1*	*2*	*0*	*0*	*0*	*1*	*0*	*0*	*0*	*1*

---

3   *Data Source: BCCDC. When present, "By Provider Address" is graphed as dashed line in same colour.*

4   *MSM=men who have sex with men; PWID=people who inject drugs; HET=heterosexual. NIR=No identified risk/exposure.*

Stage of HIV Infection at Diagnosis

Classification of stage of HIV infection, in the absence of information regarding recent testing history, is reliant on clinical information available at the time of diagnosis, including first CD4+ cell count and laboratory results suggestive of acute HIV infection (Table 1). The benefits of Treatment as Prevention (TasP) are maximized when antiretroviral therapy (ART) is initiated at high CD4 cell counts. Accordingly, it is preferable that individuals newly diagnosed with HIV be in the early stages of HIV infection (stage 0 or 1) to allow for early ART initiation.

N.B. Interpretation of Stage of HIV Infection at Diagnosis should proceed with caution. Early increases in diagnosis at late stage (i.e., low CD4 counts) may represent a "catching up" of previously missed long term infected individuals rather than a trend toward diagnosis at later stage of infection.

Indicator 4. Stage of HIV Infection at Diagnosis

Table 1 Staging Classifications of Infection at Time of HIV Diagnosis Based on CDC HIV Surveillance Case Definitions

Stage	Criteria	
0	Laboratory criteria met for acute HIV infection, or previous negative or indeterminate HIV test within 180 days of first confirmed positive HIV test.	
1	Stage 0 not met *and*	CD4 ≥500
2a		CD4 350–499
2b		CD4 200–349
3		CD4 <200
Unknown		No available CD4

Updated 2016 Q1: AIDS diagnosis date is no longer used in this indicator.

Figure 4.1 Stage of HIV Infection at Diagnosis for Northern Health, 2011–2015 [5]

Figure 4.2 Stage of HIV Infection at Diagnosis by Gender for Northern Health, 2011–2015 [5]

	Northern Health					Female					Male				
	2011	'12	'13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15
Stage 0	3	0	3	4	0	2	0	2	2	0	1	0	1	2	0
Stage 1	5	5	3	0	1	2	1	0	0	0	3	4	3	0	1
Stage 2a	2	2	1	3	0	1	1	0	0	0	1	1	1	3	0
Stage 2b	7	2	3	3	1	2	1	1	1	1	5	1	2	2	0
Stage 3	3	2	6	2	3	1	0	1	0	1	2	2	5	2	2
Unknown	4	1	1	2	1	2	0	0	0	1	2	1	1	2	0
Total *(n=)*	24	12	17	14	6	10	3	4	3	3	14	9	13	11	3

Figure 4.3 Stage of HIV Infection at Diagnosis by Age Category for Northern Health, 2011–2015 [5]

Figure 4.4 Stage of HIV Infection at Diagnosis by Exposure Category for Northern Health, 2011–2015 [5,6]

	< 30 years					30–39 years					40–49 years					≥ 50 years					MSM					PWID					Heterosexual					Other					NIR/Unknown				
	2011	12	13	14	15	11	12	13	14	15	11	12	13	14	15	11	12	13	14	15	11	12	13	14	15	11	12	13	14	15	11	12	13	14	15	11	12	13	14	15	11	12	13	14	15
Stage 0	1	0	0	1	0	1	0	2	0	0	1	0	0	0	0	0	0	1	3	0	0	0	1	1	0	1	0	1	1	0	2	0	1	1	0	0	0	0	1	0	0	0	0	0	0
Stage 1	1	1	0	0	0	1	0	3	0	1	1	1	0	0	0	2	3	0	0	0	0	1	1	0	0	1	1	1	0	0	4	3	1	0	1	0	0	0	0	0	0	0	0	0	0
Stage 2a	2	0	1	2	0	0	0	0	1	0	0	0	0	0	0	0	2	0	0	0	0	0	0	1	0	2	1	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	1	0
Stage 2b	0	0	0	0	0	3	1	0	0	0	3	1	0	2	0	1	0	3	1	1	3	0	0	0	0	3	1	2	1	0	1	0	1	1	0	1	0	1	1	0	0	0	0	0	1
Stage 3	1	0	0	0	0	2	0	2	0	1	0	1	1	0	1	0	1	3	2	1	0	0	1	0	0	1	1	5	2	1	2	1	0	0	1	0	0	0	0	0	0	0	0	0	1
Unknown	1	0	0	1	0	2	0	0	1	1	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	1	3	0	1	0	0	0	0	1	0	0	1	1	0	0	0
Total (n=)	6	1	1	4	0	9	1	7	2	3	5	4	2	2	1	4	6	7	6	2	3	1	3	2	0	8	4	9	6	2	11	6	4	2	2	1	0	1	3	0	1	1	0	1	2

5   *Data Source:* BCCDC

6   MSM=*men who have sex with men;* PWID=*people who inject drugs;* HET=*heterosexual.* NIR=*No identified risk/exposure.*

HIV Cascade of Care

Indicator 5. HIV Cascade of Care

The success of seek, test, treat and retain (STTR) strategies like STOP is reliant on early diagnosis of HIV, linking newly diagnosed HIV-positive persons with ongoing care, retaining persons in HIV-care; initiating ART based on best evidenced practices and maintaining optimal ART adherence to ensure a suppressed viral load. These stages of HIV-care can be summarized as: 1. HIV diagnosis, 2. Linked to HIV care, 3. Retained in HIV care, 4. On ART, 5. Adherent to ART and 6. Achieving a suppressed VL; collectively, they are referred to as the cascade of care. Attrition between any of these stages of HIV-care means a reduction in the potential of ART as a benefit to the HIV-positive individual and as an HIV transmission prevention method on a population level. Thus, when interpreting trends in the cascade of care, we strive to see increases along each step of the cascade of care (i.e. reduced attrition) with the ultimate goal being 100% within each stage of the cascade. Monitoring the Cascade of Care provides a picture as to where deficiencies lie in the delivery and uptake of HIV-care. In this section we present the cascade of care for the period 2015 Q3–2016 Q2 in Northern Health and stratified by sex and age.

Figure 5.1   Estimated Cascade of Care for Northern Health, Year Ending 2016 Q2 [7]

Figure 5.2   Estimated Cascade of Care for Northern Health by Gender, Year Ending 2016 Q2 [7]

7   *Data is for the period 2015 Q3–2016 Q2.*
    Data Sources:
    i   *British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).*
    ii   *Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).*

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider.
If the most recent HA of residence is not updated then the designated HA may be incorrect.

NB: Transgender have been assigned to their biological sex.

Figure 5.3   Estimated Cascade of Care for Northern Health by Age Category, Year Ending 2016 Q2 [8]

8   Data is for the period 2015 Q3–2016 Q2.
     Data Sources:
     i   British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).
     ii   Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

     Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider.
     If the most recent HA of residence is not updated then the designated HA may be incorrect.

Figure 5.4   Estimated Cascade of Care for Northern Health by MSM Status, Year Ending 2016 Q2 [9]

9   *Data is for the period 2015 Q3–2016 Q2.*
     Data Sources:
    i   *British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).*
    ii   *Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).*

     Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider.
     If the most recent HA of residence is not updated then the designated HA may be incorrect.

Figure 5.5   Estimated Cascade of Care for Northern Health by Age Category and MSM Status, Year Ending 2016 Q2 [9]

MSM

Non-MSM

Unknown

| < 30 n≤5 | 30–39 n≤5 | 40–49 n=7 | ≥ 50 n=26 | < 30 n=6 | 30–39 n=38 | 40–49 n=49 | ≥ 50 n=72 | < 30 n=14 | 30–39 n=18 | 40–49 n=20 | ≥ 50 n=37 |

% of Diagnosed

% Loss from Previous Stage

100% 80% 60% 40% 20% 0% −20% −40% −60% −80% −100%

---

9   *Data is for the period 2015 Q3–2016 Q2.*
Data Sources:
i   *British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).*
ii   *Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).*

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider.
If the most recent HA of residence is not updated then the designated HA may be incorrect.

Figure 5.6   Estimated Cascade of Care for Northern Health by History of IDU, Year Ending 2016 Q2 [9]

[9]   *Data is for the period 2015 Q3–2016 Q2.*
      Data Sources:
      i   British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).
      ii   Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

      Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider.
   *If the most recent HA of residence is not updated then the designated HA may be incorrect.*

Figure 5.7　　　Estimated Cascade of Care for Northern Health by HSDA, Year Ending 2016 Q2 [9]

9　　Data is for the period 2015 Q3–2016 Q2.
　　Data Sources:
　　i　　British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).
　　ii　　Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

　　Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider.
　　If the most recent HA of residence is not updated then the designated HA may be incorrect.

Programmatic Compliance Score

Indicator 6. Programmatic Compliance Score (PCS)

The Programmatic Compliance Score (PCS) is a summary measure of risk of future death, immunologic failure and virologic failure from all causes for people who are starting ART for the first time. It is composed of patient- and physician-driven effects. PCS scores range from 0–6 with higher scores indicative of poorer health outcomes and greater risk of death. Table 2 provides mortality, immunologic failure and virologic failure probabilities for given PCS scores. We interpret an individual with a PCS≥4 as being 22 times more likely to die, almost 10 times more likely to have immunologic failure and nearly 4 times as likely to demonstrate virologic failure compared to those individuals with a PCS score of 0. A detailed description of how the PCS score is calculated and its validation can be found in the technical report. In short, PCS scores are calculated by summing the results (yes=1, no=0) of six un-weighted non-performance indicators based on IAS–USA treatment guidelines:

1. having <3 CD4 cell count tests in the first year after starting antiretroviral therapy (ART);
2. having <3 plasma viral load (VL) tests in the first year after starting ART;
3. not having drug resistance testing done prior to starting ART;
4. starting on a non-recommended ART regimen;
5. starting therapy with CD4<200 cells/µL; and
6. not achieving viral suppression within 9 months since ART initiation.

In this section we provide PCS scores and their components over time for the province of BC. A decline to 0%, **(i.e., all individuals having a score of 0)** is the eventual goal.

Table 2. Probability of Mortality, Immunologic Failure and Virologic Failure based on the Programmatic Compliance Score

Programmatic Compliance Score	Mortality Risk Ratio (95% Confidence Interval)	Immunologic Failure Risk Ratio (95% CI)	Virologic Failure Risk Ratio (95% CI)
0 (Best score)	1 (–)	1 (–)	1 (–)
1	3.81 (1.73–8.42)	1.39 (1.04–1.85)	1.32 (1.05–1.67)
2	7.97 (3.70–17.18)	2.17 (1.54–3.04)	1.86 (1.46–2.38)
3	11.51 (5.28–25.08)	2.93 (1.89–4.54)	2.98 (2.16–4.11)
4 or more (Worst score)	22.37 (10.46–47.84)	9.71 (5.72–16.47)	3.80 (2.52–5.73)

Reference: Lima VD, Le A, Nosyk B, Barrios R, Yip B, et al. (2012) Development and Validation of a Composite Programmatic Assessment Tool for HIV Therapy. PLoS ONE 7(11): e47859. doi:10.1371/journal.pone.0047859

Figure 6.1   PCS Components for Northern Health, 2014 Q3–2016 Q2 [10]

Non Viral Suppression at 9 Mo.

Baseline CD4 <200/µL
<3 Viral Load Tests

<3 CD4 Tests

No Baseline Genotype

Non-Recommended ART

	Q3 2014	Q4	Q1 2015	Q2	Q3	Q4	Q1 2016	Q2
n=	15	21	18	17	14	14	10	12

Figure 6.2   Historical Trends for PCS Score for Northern Health, 2014 Q3–2016 Q2 [10,11]

Distribution of PCS Score

	Q3 2014	Q4	Q1 2015	Q2	Q3	Q4	Q1 2016	Q2
n=	15	21	18	17	14	14	10	12

---

10   *Data Source: British Columbia Centre for Excellence Drug Treatment Program (DTP) Database. Limitations: CD4 cell count capture is approximately 80%.*

11   *Each quarter's data is calculated as the sum of the 4 quarters leading up to it. e.g. 2013 Q1 is calculated from 2012 Q2 – 2013 Q1. NB: A score of 0 is the best score and a score of 4 or more is the worst score.*

Antiretroviral Uptake

In this section we present trends in ART uptake, the number and proportion of new HIV treatment initiations and the number of active and inactive DTP participants. Trends in ART uptake should be interpreted under the consideration of changing BC HIV treatment guidelines. BC HIV treatment guidelines are updated regularly by the BC-CFE Therapeutic Guidelines Committee and reflect those of the International AIDS Society. Most recent changes were made in 2012 and HIV treatment is now recommended for all HIV-positive adults regardless of CD4 cell count; as evidence demonstrates that early initiation of HIV treatment maximizes both the individual's health outcomes as well as the potential of ART as a form of HIV transmission prevention at a population level. As such, trends in the number and proportion of persons on ART and new ART starts (in both naïve and experienced persons) are expected to increase over time at higher CD4 cell counts.

Indicator 7. New Antiretroviral Therapy Starts in Northern Health

Figure 7   BC-CfE Drug Treatment Program Enrollment: New ART Participants in Northern Health, 2014 Q3–2016 Q2 [12]

Indicator 8. CD4 Cell Count at ART Initiation

Figure 8   CD4 Cell Count at ART Initiation of ART-Naïve DTP Participants in Northern Health, 2014 Q3–2016 Q2 [13]

The majority of cells in this figure have n ≤ 5, which is considered statistically insignificant as well as a possible risk to patient privacy. For this reason, this figure has been omitted. Authorized parties may contact the British Columbia Centre for Excellence in HIV/AIDS to obtain this information.

---

12   *Data Source: Drug Treatment Program Database*
      Limitation: DTP participants are designated to an HA based on most current residence provided by the participant.

13   *Data Source: Drug Treatment Program Database*
      Limitations: CD4 cell count data is approximately 80% complete.

Indicator 9. Active and Inactive DTP Participants

Table 3. Distribution of People on ART for Northern Health, 2016 Q2 [14]

Age	< 30	7
	30–39	50
	40–49	64
	⩾ 50	99
Gender	Male	137
	Female	83
Exposure	MSM	30
	PWID	115
Total		220

Figure 9   Active and Inactive DTP Participants
for Northern Health, 2014 Q3–2016 Q2 [15]

14   *Data Source: Drug Treatment Program Database*
    Limitation: DTP participants are designated to an HA based on most current residence provided by the participant.

    Definition:
    'On antiretroviral therapy' defined as being on treatment in the current quarter

15   *Active DTP participants: An individual who has had medication prescribed at least once in the preceding quarter.*
    Inactive DTP participants: Persons no longer prescribed drugs through the HIV/AIDS Drug Treatment Program in the last quarter.

Antiretroviral Adherence Level

In this section we present trends in prescription refill adherence levels for individuals in their first year of treatment. Given that the benefits of ART are compromised in the presence of imperfect ART adherence, we expect to see the proportion of persons on ART achieving near perfect adherence (ie. ≥95%) to increase with time. Furthermore, it is important that trends in the proportion of ART users achieving prescription refill adherence of ≥95% keep pace with new ART starts and increase among those continuing on ART.

Indicator 10. Antiretroviral Adherence

Figure 10   Distribution of Individuals by Adherence Level in 1st
                 Year of Therapy, Based on Pharmacy Refill Compliance
                 for Northern Health, 2014 Q3–2016 Q2 [16]

The majority of cells in this figure have n ≤ 5, which is considered statistically insignificant as well as a possible risk to patient privacy. For this reason, this figure has been omitted. Authorized parties may contact the British Columbia Centre for Excellence in HIV/AIDS to obtain this information.

---

16   *Data Source: Drug Treatment Program Database*
      Limitation: Prescription refill adherence is used as a proxy for patient adherence.

Resistance Testing and Results

Indicator 11. Resistance Testing and Results

In this section, we present trends in cumulative resistance testing by resistance category: Suppressed (where a DTP participant's viral load is too low to be genotyped); Wild Type (where no HIV treatment resistances were discovered), Never Genotyped, and Resistances to one, two, three, or four HIV treatment classes. Resistance testing prior to ART initiation is recommended in the BC HIV treatment primary care guidelines. Thus, it is expected that trends over time should find all persons enrolled in the DTP to have been genotyped. Trends over time should also show an increase in the proportion of DTP participants achieving a suppressed status and an increase in resistance testing should not lead to an increase in the number of ART resistances occurring.

Figure 11   Cumulative Resistance Testing Results by Resistance Category for Northern Health, 2014 Q3–2016 Q2 [17]

17   *Data Source: Drug Treatment Program Database*

     Limitation: DTP participants are designated to a HA based on most current residence provided by the participant.

AIDS-Defining Illness

Indicator 12. AIDS-Defining Illness

Improvements in ART and the expansion of ART province-wide has led to very low numbers of recorded AIDS cases across BC. However, interpreting trends in AIDS cases is challenging as AIDS reporting is passive in BC and it is likely that they are under-reported across all Health Authorities. In addition to under-reporting, methods of reporting AIDS cases are inconsistent across HA's and do not truly reflect the current reality of new AIDS diagnoses. Efforts will need to be made to improve under- and inconsistent reporting of AIDS cases across all HA's. The table below shows AIDS cases using three definitions. First, AIDS cases were defined as the number of physician-reported AIDS defining illness (ADI) in a given year. AIDS case reporting is a passive process and physicians can voluntarily report AIDS cases to the BCCDC or DTP. As such, we have plotted both BCCDC reports and DTP reported AIDS cases. We also show the proportion of persons initiating ART with a CD4<200 cells/μL.

Figure 12   AIDS Case Rate and Reports for Northern Health [18]

		2008	2009	2010	2011	2012	2013	2014	2015
CD4<200 at ART initiation	CASES	14	16	10	13	7	9	≤ 5	≤ 5
	PER 100K	5.0	5.7	3.6	4.6	2.5	3.2	1.8	1.1
AIDS: DTP Reports	CASES	≤ 5	6	7	≤ 5	≤ 5	7	8	≤ 5
	PER 100K	1.1	2.1	2.5	1.8	1.1	2.5	2.8	1.4
AIDS: BCCDC Reports	CASES	≤ 5	8	≤ 5	6	≤ 5	6	9	–
	PER 100K	1.1	2.9	1.1	2.1	0.4	2.1	3.1	–

18   *Data Source: DTP AIDS cases are obtained from the Drug Treatment Program Database; BCCDC AIDS cases are obtained from the BC-CDC; CD4<200 at ART initiation data came from the DTP database.*

Limitation: AIDS case reporting was investigated using 3 definitions: First, using AIDS cases reported in AIDS case report forms from the DTP; Second, using AIDS cases reported via the BCCDC and third, using a CD4 cell count of <200 cells/μL at time of ART initiation using DTP data. AIDS case reporting is passive in BC, thus; AIDS case reporting is not well captured. The DTP sends out AIDS reporting forms to physicians annually. The BCCDC uses DTP AIDS case reports as well as physician AIDS case reports made directly to the BCCDC. Interpreting AIDS case reports should be done with these limitations in mind. AIDS data is updated annually as very few AIDS cases reports are reported in general and trends would be difficult to notice if reported quarterly.

HIV-Related Mortality
Indicator 13. HIV-Related Mortality

Evidence indicates that individuals who initiate treatment with recommended ART in a timely fashion may live near normal lifespans. Excess mortality among HIV positive persons is, therefore, an important measure of HIV care with a goal of minimizing HIV-related mortality in British Columbia.

Figure 13   HIV-Related Deaths by Year for Northern Health, 2004–2011 [19]

	2004	2005	2006	2007	2008	2009	2010	2011
HIV-Related Deaths	7	6	7	8	6	≤5	≤5	≤5
Per 100 HIV+ Population	2.28	1.92	2.21	2.47	1.81	0.89	1.45	1.42
Per 100,000 Population	2.30	1.95	2.42	2.75	2.11	1.05	1.73	1.72

---

19   *Data Source: BC Vital Statistics*

     Limitation:

     1. DTP participants are designated to an HA based on most current residence provided by the participant.

     2. Mortality data is updated annually.

     3. The most recent available data was used.

Appendices

Indicator 1: Test Episodes (thousands)

		2011 Q3	Q4	2012 Q1	Q2	Q3	Q4	2013 Q1	Q2	Q3	Q4	2014 Q1	Q2	Q3	Q4	2015 Q1	Q2	Q3	Q4	2016 Q1	Q2
Northern Health		1.9	1.9	2.3	2.2	2.2	2.3	2.7	2.7	2.6	2.6	3.1	3.0	2.9	3.0	3.7	3.2	3.2	3.2	3.7	3.3
Gender	Female	1.0	1.0	1.2	1.1	1.2	1.2	1.3	1.4	1.3	1.3	1.6	1.5	1.5	1.5	1.9	1.6	1.6	1.6	1.9	1.7
	Male	0.8	0.8	1.1	1.0	1.0	1.1	1.2	1.2	1.1	1.2	1.4	1.3	1.3	1.4	1.6	1.4	1.5	1.4	1.6	1.5
	Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Age	< 30	0.8	0.8	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0	0.9	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.0
	30–39	0.4	0.4	0.5	0.5	0.5	0.4	0.6	0.5	0.5	0.5	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.7	0.6
	40–49	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.5	0.4	0.4	0.5	0.6	0.5	0.5	0.5	0.6	0.5
	≥ 50	0.3	0.3	0.5	0.4	0.5	0.5	0.6	0.6	0.6	0.7	0.9	0.8	0.8	0.9	1.3	0.9	0.9	0.9	1.1	1.1
POC HIV Tests (not in thousands)		54	52	83	74	60	65	137	123	151	110	139	137	91	102	183	71	125	124	144	94
Northeast		0.4	0.4	0.5	0.5	0.4	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.5	0.5	0.6	0.6	0.5
Female		0.3	0.2	0.3	0.3	0.2	0.2	0.3	0.3	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.3
Male		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Northern Interior		1.0	1.1	1.4	1.2	1.3	1.4	1.6	1.6	1.6	1.6	2.0	1.9	1.8	1.9	2.6	2.0	2.0	1.9	2.3	2.2
Female		0.5	0.6	0.7	0.6	0.6	0.7	0.7	0.8	0.8	0.7	1.0	0.9	0.9	0.9	1.3	1.0	1.0	0.9	1.2	1.1
Male		0.5	0.5	0.6	0.6	0.6	0.7	0.7	0.7	0.7	0.7	0.9	0.8	0.8	0.8	1.1	0.9	0.9	0.8	1.0	1.0
Northwest		0.4	0.4	0.5	0.5	0.5	0.5	0.6	0.5	0.5	0.6	0.6	0.6	0.6	0.7	0.7	0.7	0.6	0.7	0.8	0.7
Female		0.3	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.3	0.3	0.3	0.3	0.4	0.4	0.3	0.4	0.5	0.3
Male		0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3

Indicator 2: Rate of HIV Testing per 100,000

		2009	2010	2011	2012	2013	2014	2015
All Northern Health		2290.7	2349.0	2431.8	2909.8	3333.0	3825.8	4347.2
Northeast		2289.8	2246.2	2343.4	2563.9	2621.4	2548.7	2946.7
Northern Interior		2360.2	2450.0	2563.9	3222.0	3801.1	4644.3	5290.5
Northwest		2158.9	2248.3	2259.0	2633.2	3109.1	3499.8	3914.8
Gender	Female	2412.8	2542.7	2622.2	3102.4	3618.7	4196.5	4712.5
	Male	2106.3	2123.3	2213.0	2685.1	3021.7	3427.5	3934.9
Age	< 30	2400.7	2474.8	2611.1	2971.6	3122.6	3201.6	3494.6
	30–39	4263.7	4336.5	4440.8	4754.5	5245.2	5811.3	6019.4
	40–49	2448.1	2541.9	2670.1	3215.1	3614.2	4331.3	5113.3
	≥ 50	1198.4	1243.5	1291.6	1976.9	2719.3	3576.2	4356.9

Indicator 3: New HIV Diagnoses

		2011 Q3	Q4	2012 Q1	Q2	Q3	Q4	2013 Q1	Q2	Q3	Q4	2014 Q1	Q2	Q3	Q4	2015 Q1	Q2	Q3	Q4	2016 Q1	Q2
Northern Health	By Client Residence	5	5	5	4	3	0	3	8	3	3	2	5	4	2	1	2	2	1	2	4
	By Provider Address	5	6	5	4	3	0	3	8	3	3	2	5	3	2	1	2	2	1	3	4
Gender	Female	1	3	1	2	0	0	0	3	1	0	1	0	1	1	0	0	2	1	2	0
	Male	4	2	4	2	3	0	3	5	2	3	1	5	3	1	1	2	0	0	0	4
Age	< 30	1	2	1	0	0	0	0	2	0	0	0	1	2	1	0	0	0	0	2	0
	30–39	1	2	0	1	0	0	0	5	0	1	1	0	0	1	0	2	1	0	0	1
	40–49	2	0	1	2	2	0	1	0	0	1	1	0	0	0	1	0	0	0	0	1
	≥ 50	1	1	3	1	1	0	2	1	3	1	0	4	2	0	0	0	1	1	0	2
Exposure	MSM	1	1	0	0	1	0	1	1	0	1	0	1	1	0	0	0	0	0	–	–
	PWID	1	3	3	2	1	0	0	2	0	2	1	0	0	1	1	1	0	0	–	–
	HET	3	1	2	2	0	0	2	5	2	0	1	3	1	1	0	1	1	0	–	–
	Other	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	0	–	–
	NIR/Unknown	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	1	1	–	–

Indicator 3: New HIV Diagnoses (cont'd)

		2011		2012				2013				2014				2015				2016	
		Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Northeast	By Client Residence	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0
	By Provider Address	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*1*	*0*	*0*	*1*	*0*	*0*	*0*	*0*
Northern Interior	By Client Residence	4	4	2	4	2	0	3	6	2	3	1	2	3	1	1	1	1	1	2	3
	By Provider Address	*4*	*4*	*2*	*4*	*2*	*0*	*3*	*7*	*2*	*3*	*1*	*3*	*3*	*1*	*1*	*1*	*1*	*1*	*3*	*3*
Northwest	By Client Residence	1	1	3	0	1	0	0	2	1	0	1	3	1	0	0	1	0	0	0	1
	By Provider Address	*1*	*2*	*3*	*0*	*1*	*0*	*0*	*1*	*1*	*0*	*1*	*2*	*0*	*0*	*0*	*1*	*0*	*0*	*0*	*1*

Indicator 4: Stage of HIV Infection at Baseline

	Northern Health					Female					Male					< 30 years					30–39 years					40–49 years				
	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15
Stage 0	3	0	3	4	0	2	0	2	2	0	1	0	1	2	0	1	0	0	1	0	1	0	2	0	0	1	0	0	0	0
Stage 1	5	5	3	0	1	2	1	0	0	0	3	4	3	0	1	1	1	0	0	0	1	0	3	0	1	1	1	0	0	0
Stage 2a	2	2	1	3	0	1	1	0	0	0	1	1	1	3	0	2	0	1	2	0	0	0	0	1	0	0	0	0	0	0
Stage 2b	7	2	3	3	1	2	1	1	1	1	5	1	2	2	0	0	0	0	0	0	3	1	0	0	0	3	1	0	2	0
Stage 3	3	2	6	2	3	1	0	1	0	1	2	2	5	2	2	1	0	0	0	0	2	0	2	0	1	0	1	1	0	1
Unknown	4	1	1	2	1	2	0	0	0	1	2	1	1	2	0	1	0	0	1	0	2	0	0	1	1	0	1	1	0	0
Total	24	12	17	14	6	10	3	4	3	3	14	9	13	11	3	6	1	1	4	0	9	1	7	2	3	5	4	2	2	1

	≥ 50 years					MSM					PWID					Heterosexual					Other Exposure					NIR/Unknown				
	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15
Stage 0	0	0	1	3	0	0	0	1	1	0	1	0	1	1	0	2	0	1	1	0	0	0	0	1	0	0	0	0	0	0
Stage 1	2	3	0	0	0	0	1	1	0	0	1	1	1	0	0	4	3	1	0	1	0	0	0	0	0	0	0	0	0	0
Stage 2a	0	2	0	0	0	0	0	0	1	0	2	1	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	1	0
Stage 2b	1	0	3	1	1	3	0	0	0	0	3	1	2	1	0	0	1	0	1	0	1	0	1	1	0	0	0	0	0	1
Stage 3	0	1	3	2	1	0	0	1	0	0	1	1	5	2	1	2	1	0	0	1	0	0	0	0	0	0	0	0	0	1
Unknown	1	0	0	0	0	0	0	0	0	0	0	0	0	1	1	3	0	1	0	0	0	0	0	1	0	1	1	0	0	0
Total	4	6	7	6	2	3	1	3	2	0	8	4	9	6	2	11	6	4	2	2	1	0	1	3	0	1	1	0	1	2

Indicator 5: HIV Cascade of Care

			DIAGNOSED	LINKED	RETAINED	ON ART	ADHERENT	SUPPRESSED
Northern Health			294	274	241	222	189	132
Age Category	< 30		23	16	14	12	10	7
	30–39		60	56	51	48	33	19
	40–49		76	75	64	59	53	34
	≥ 50		135	127	112	103	93	72
Age Category and MSM Status	MSM	< 30	≤ 5	≤ 5	≤ 5	≤ 5	≤ 5	≤ 5
		30–39	≤ 5	≤ 5	≤ 5	≤ 5	≤ 5	≤ 5
		40–49	7	7	5	5	5	3
		≥ 50	26	24	23	19	17	13
	Non-MSM	< 30	6	6	3	2	0	0
		30–39	38	38	38	37	27	15
		40–49	49	49	43	40	35	21
		≥ 50	72	71	66	63	57	43
	Unknown	< 30	14	7	7	7	7	6
		30–39	18	15	10	9	5	3
		40–49	20	19	16	14	13	10
		≥ 50	37	32	23	21	19	16
Gender	Male		181	170	151	137	126	89
	Female		112	104	90	85	63	43
Injection Drug Use	PWID		135	132	123	116	97	64
	Non-PWID		104	103	89	81	69	50
	Unknown		54	39	29	25	23	18
MSM Status	MSM		39	38	34	29	26	18
	Non-MSM		166	163	151	142	119	79
	Unknown		89	73	57	51	44	35
Health Authority	Northeast		40	39	27	25	23	16
	Northern Interior		190	177	158	147	122	87
	Northwest		65	60	57	50	44	29

Indicator 6: **Programmatic Compliance Score (PCS)**

	2014		2015				2016	
	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
< 3 CD4 Tests	0.0%	4.8%	5.6%	0.0%	0.0%	0.0%	10.0%	16.7%
< 3 Viral Load Tests	0.0%	4.8%	5.6%	0.0%	7.1%	14.3%	20.0%	33.3%
No Baseline Genotype	0.0%	0.0%	0.0%	0.0%	0.0%	7.1%	10.0%	8.3%
Baseline CD4 < 200 cells/µL	46.7%	42.9%	27.8%	35.3%	21.4%	28.6%	30.0%	33.3%
Non-Recommended ART	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Non Viral suppression at 9 Mo.	60.0%	57.1%	44.4%	41.2%	28.6%	35.7%	30.0%	50.0%
PCS Score: 0	3	5	7	6	7	5	3	3
PCS Score: 1	8	10	8	9	6	6	4	3
PCS Score: 2	4	5	2	2	1	3	3	4
PCS Score: 3	0	1	1	0	0	0	0	2
PCS Score: 4 or more	0	0	0	0	0	0	0	0
Total (n=)	15	21	18	17	14	14	10	12

Indicator 7: **New DTP ARV Participants**

	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
First Starts	4	5	3	4	3	4	1	4
Experienced Starts	6	2	3	5	4	4	7	7

Indicator 8: **CD4 Cell Count at ART Initiation for ARV-Naïve DTP Participants**

	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
CD4 ≥ 500	–	–	–	–	–	–	–	–
CD4 350–499	–	–	–	–	–	–	–	–
CD4 200–349	–	–	–	–	–	–	–	–
CD4 50–199	–	–	–	–	–	–	–	–
CD4 < 50	–	–	–	–	–	–	–	–
CD4 Median (cells/µL)	–	–	–	–	–	–	–	–
Total (n=)	≤ 5	≤ 5	≤ 5	≤ 5	≤ 5	≤ 5	≤ 5	≤ 5

Indicator 9: **Active and Inactive DTP Participants**

	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Active DTP Participants	220	226	219	224	216	216	215	220
Inactive DTP Participants	36	36	35	36	38	39	39	41

Indicator 10: **Antiretroviral Adherence**

	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
≥ 95%	5	5	–	–	–	–	–	–
80% to < 95%	2	2	–	–	–	–	–	–
40% to < 80%	0	0	–	–	–	–	–	–
< 40%	0	0	–	–	–	–	–	–
Total (n=)	7	7	≤ 5	≤ 5	≤ 5	≤ 5	≤ 5	≤ 5

Indicator 11: **Resistance Testing and Results**

	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Suppressed	128	111	107	122	104	116	119	113
Wild Type	26	21	20	17	27	19	13	16
Never Genotyped	1	1	0	2	0	0	0	0
1-Class	10	14	11	9	7	9	8	7
2-Class	2	2	2	1	1	0	1	1
3-Class	0	0	0	0	0	0	0	0
Total (n=)	167	149	140	151	139	144	141	137

Indicator 12: **AIDS-Defining Illness**

		2007	2008	2009	2010	2011	2012	2013	2014	2015
CD4 < 200 at	Cases	15	14	16	10	13	7	9	≤ 5	≤ 5
ART initiation	*Rate per 100,000*	*5.4*	*5.0*	*5.7*	*3.6*	*4.6*	*2.5*	*3.2*	*1.8*	*1.1*
AIDS Cases	Cases	6	≤ 5	6	7	≤ 5	≤ 5	7	8	≤ 5
(DTP Reports)	*Rate per 100,000*	*2.1*	*1.1*	*2.1*	*2.5*	*1.8*	*1.1*	*2.5*	*2.8*	*1.4*
AIDS Cases	Cases	≤ 5	≤ 5	8	≤ 5	6	≤ 5	6	9	–
(BCCDC Reports)	*Rate per 100,000*	*1.8*	*1.1*	*2.9*	*1.1*	*2.1*	*0.4*	*2.1*	*3.1*	–

Indicator 13: **HIV-Related Mortality**

	2004	2005	2006	2007	2008	2009	2010	2011
Northern Health	7	6	7	8	6	≤5	≤5	≤5
Per 100 HIV+ Population	2.28	1.92	2.21	2.47	1.81	0.89	1.45	1.42
Per 100,000 Population	2.30	1.95	2.42	2.75	2.11	1.05	1.73	1.72